TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Urinary excretion of PB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PB concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mucosal petechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: amount of gastric microbleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall HPV prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall agreement between S-WET and S-DRY
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for cervical intraepithelial neoplasia grade one (CIN1) or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Successful intubation on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ventricular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak plasma loperamide concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total area under the plasma loperamide concentration-time curve (AUC(0-infinity))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life (t(1/2)) of loperamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk difference in outcomes between LHW and clinic nurse supervision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk difference in outcomes between LHW and self supervision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sum of 4 SFTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Median time to recurrence of any mood symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: readiness to change (recognition subscale)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: self efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: dependency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Symptoms at the local injection site
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma lignan concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of TrA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability indexes of standing with eyes open
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stability indexes of standing on the pillow with eyes closed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of STD screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sense of meaning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nasal steroid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: emergence of withdrawal symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with greater than 50% decline in PSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: feedback-related oscillatory power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD4(+) T cell count increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum interferon (IFN)‐γ levels increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: appetite ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clearance rate of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased bleeding risk
Endpoint domain: Adverse events/effects
Primary endpoint: composite of cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of 'most useful' sentences completed
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dwell frequencies of primary flight instruments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal Densitometry (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-cog11 score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: DAD score change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Binding of GADA to T1D-associated b96.11-defined epitope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean overall MHQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Ulnar deviation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Extensor lag improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of critical illness polyneuropathy/myopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prolonged mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Asymptomatic VTE rate
Endpoint domain: Mortality/survival
Primary endpoint: Grade 3 intrameniscal signal abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gastric emptying (GE) delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Antral motility effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Herpes Zoster Incidence Rates (HZ IRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Composite Autonomic Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High-frequency heart rate variability at night
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: papilla height increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-implant mucosal margin recession
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS patients' perceptions of esthetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cycling time to exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elbow-flexion force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: BMI-SD scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycosylated-haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FACIT-F fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: peak impact forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: body braking time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccination titers for Bordetella pertussis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Body temperature increase after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep duration after vaccination
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Neonatal TSH values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: CRAMP level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altered gene expression associated with soy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: stair climb time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoblastic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma HIV RNA below detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anxiolytic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Pressure (BP) change after standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate (HR) change after standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Homocysteine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Volume of apparent DWI lesion reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort upon repeat ligamentous probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capsular distension sensation after injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: working memory processing efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nevirapine trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical symptoms attributed to nevirapine
Endpoint domain: Adverse events/effects
Primary endpoint: HIV-1 antibody positivity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of T helper cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymphocyte transformation response to PWM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal salivary alpha-amylase levels directly after delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of respiratory distress morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Heart Rate (HR) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of asymptomatic bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of mandibular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rates in AFL and AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall satisfaction with study information
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in PAM scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease in social/role activity limitations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Greater life satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SPID(48) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: viable epidermal thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: dermoepidermal junction undulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: new blood vessel formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: physiological indices of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-10 median values postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NRS scale values postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8(+) T-cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ankle dorsiflexion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete clinical clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete histopathological clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 (forced expiratory volume in 1 s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Interscan variability for disc normality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interscan variability for general degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interscan variability for disc herniation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at mammography screening
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Postoperative hip-knee angle within 3° of neutral alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight loss of at least 1 kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physiotherapy length of stay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Uncorrected visual acuity (UCVA) of 20/40 or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in residual refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of gastric neoplasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in vertical defect height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in horizontal defect width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss in augmentation thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: level of knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean cognitive change over time
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Major adverse cardiac events (MACE) at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Level of state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Level of alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in the stage of pressure ulcers (PUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in the surface area of pressure ulcers (PUs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eMRI score as a measure of joint status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of pain due to propofol injection
Endpoint domain: Adverse events/effects
Primary endpoint: LVMi (Left Ventricular Mass index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SF-36 role physical scale scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difficulty eating/swallowing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Difficulty driving
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of panic disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric composite score on the ASI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in polypharmacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentrations of Cu
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of Fe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentrations of Ca
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Crestal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Mean papillary fill
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EDV/ESV improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MIBI uptake in infarction territory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in stool form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Dyspnea-related disability improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in MASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fraction of time with BIS levels of 40-60
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective opinions on utility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of children with protective antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of vitamin A, E, C, and selenium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythrocyte GSH-Px activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall satisfaction rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hr VAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean roughness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Global health status (GHS)/Quality of Life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to worsening of Eastern Cooperative Oncology Group performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day stroke risk
Endpoint domain: Adverse events/effects
Primary endpoint: Tooth whitening improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPE emission intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Termination of hemodynamically stable ventricular tachycardias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Less abrasion of the gingiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pleasure of use
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall Survival (OS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin toxicity from erlotinib
Endpoint domain: Adverse events/effects
Primary endpoint: strength of external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment-emergent mania
Endpoint domain: Adverse events/effects
Primary endpoint: Mean decreases in YMRS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean decreases in CGI-BP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Parasite elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: event-free time gained
Endpoint domain: Mortality/survival
Primary endpoint: Overall satisfaction with cabotegravir LA
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preference for cabotegravir LA vs oral cabotegravir
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: scores of executive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Loss of light perception
Endpoint domain: Adverse events/effects
Primary endpoint: Subconjunctival hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Mean time to achieve full continence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-operation for continuous stress urinary incontinence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Procedural costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Left ventricular remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Long-term benefits of psychological therapies
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life